P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

D Zhang, W Zhang, C Ming, X Gao, H Yuan, X Lin… - Neuron, 2024 - cell.com
Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …
被引用次数：11 相关文章

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.

D Zhang, W Zhang, C Ming, X Gao, H Yuan, X Lin… - Neuron, 2024 - europepmc.org
Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

D Zhang, W Zhang, C Ming, X Gao, H Yuan, X Lin… - Neuron, 2024 - Elsevier
Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

D Zhang, W Zhang, C Ming, X Gao, H Yuan… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed
so far can halt AD-associated neurodegeneration. Here, we developed a monoclonal …